@inproceedings{8763362,
  abstract     = {{The rapid emergence and spread of multi- and extensively drug-resistant bacteria are a major public health threat. Antibiotic-resistant bacteria are projected to kill 10 million people by 2050, thereby outnumbering cancer-related deaths. Today, no new antibiotic classes have been introduced since over 50 years. The once successful Waksman platform for the discovery of natural antibiotics is largely depleted. So, the spreading antibiotic resistance and the unprecedented void in the discovery of novel antibiotics increasingly leads to a highly reduced number of therapeutic options. Therefore, new discovery platforms are needed to identify new antibacterials to replenish the portfolio of antibiotics. Lysins or bacteriophage-encoded peptidoglycan hydrolases are a novel, alternative potential class of antibiotics. They are generally highly specific at the species level and thus have a narrow spectrum. Yet, we and others claim that more novel lysin candidates must be discovered to feed the (pre)clinical pipeline. Given the natural abundance of bacteriophages, lysins can be found against any bacterium. The largely unexplored metagenome from uncultivable bacteriophages is still a practically infinite reservoir of potentially powerful lysins. In this regard, we elucidate a concept about the development of a highly performant discovery platform for novel lysin-based antibiotics. The platform is driven by functional metagenomics, starting from the untapped metagenomic reservoirs.}},
  author       = {{Duyvejonck, Lisa and Pottie, Iris and Briers, Yves}},
  booktitle    = {{Viruses of Microbes 2022, Abstracts}},
  keywords     = {{Antibiotics,lysins,discovery platform,functional metagenomics}},
  language     = {{eng}},
  location     = {{Guimarães, Portugal}},
  title        = {{Towards a high-throughput lysin discovery platform based on functional metagenomics}},
  year         = {{2022}},
}